Literature DB >> 15101687

Medicinal chemistry and pharmacology of cyclic ADP-ribose.

Barry V L Potter1, Timothy F Walseth.   

Abstract

Cyclic ADP-ribose (cADPR) is a signaling molecule that has been shown to regulate calcium mobilization from intracellular stores in a wide variety of biological systems. Synthesis of structural analogs of cADPR has provided insights into structure-activity relationships as well as produced pharmacological research tools with useful properties such as, hydrolysis-resistance and cell permeability. The first generation of cADPR analogs was synthesized by a chemo-enzymatic approach that took advantage of the broad substrate specificity of Aplysia ADP-ribosyl cyclase. Analogs synthesized by this approach provided useful structure-activity information, including the importance of the 8-position of the adenine in determining agonistic or antagonistic activity and of the 3'-hydroxyl group of the southern ribose for activity. Hydrolysis resistant analogs were generated by replacing the southern ribose with a carbocyclic structure or by replacing the adenine ring with 7-deaza- or 3-deaza-adenine. Approaches to synthesize cADPR analogs by total chemical approaches have been recently reported. These approaches allow the synthesis of analogs with stable linkages between N1 of adenine and the northern ribose (or surrogate) that are not possible with the enzymatic strategy. This review will focus on the synthesis and properties of analogs that have been shown to have utility in dissecting the role of cADPR in calcium signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15101687     DOI: 10.2174/1566524043360744

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  16 in total

1.  Cellular effects and metabolic stability of N1-cyclic inosine diphosphoribose and its derivatives.

Authors:  T Kirchberger; G Wagner; J Xu; C Cordiglieri; P Wang; A Gasser; R Fliegert; S Bruhn; A Flügel; F E Lund; L-H Zhang; B V L Potter; A H Guse
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

Review 2.  Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity.

Authors:  Frances E Lund
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

3.  Design, Synthesis, and Chemical and Biological Properties of Cyclic ADP-4-Thioribose as a Stable Equivalent of Cyclic ADP-Ribose.

Authors:  Takayoshi Tsuzuki; Satoshi Takano; Natsumi Sakaguchi; Takashi Kudoh; Takashi Murayama; Takashi Sakurai; Minako Hashii; Haruhiro Higashida; Karin Weber; Andreas H Guse; Tomoshi Kameda; Takatsugu Hirokawa; Yasuhiro Kumaki; Mitsuhiro Arisawa; Barry V L Potter; Satoshi Shuto
Journal:  Messenger (Los Angel)       Date:  2014-06-01

4.  CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation.

Authors:  Seon-Young Kim; Baik Hwan Cho; Uh-Hyun Kim
Journal:  J Biol Chem       Date:  2009-11-12       Impact factor: 5.157

5.  Synthesis of cyclic adenosine 5'-diphosphate ribose analogues: a C2'endo/syn "southern" ribose conformation underlies activity at the sea urchin cADPR receptor.

Authors:  Christelle Moreau; Gloria A Ashamu; Victoria C Bailey; Antony Galione; Andreas H Guse; Barry V L Potter
Journal:  Org Biomol Chem       Date:  2010-10-25       Impact factor: 3.876

6.  Aberrant cyclization affords a C-6 modified cyclic adenosine 5'-diphosphoribose analogue with biological activity in Jurkat T cells.

Authors:  Christelle Moreau; Tanja Kirchberger; Bo Zhang; Mark P Thomas; Karin Weber; Andreas H Guse; Barry V L Potter
Journal:  J Med Chem       Date:  2012-02-08       Impact factor: 7.446

7.  Total synthesis of a cyclic adenosine 5'-diphosphate ribose receptor agonist.

Authors:  Joanna M Swarbrick; Barry V L Potter
Journal:  J Org Chem       Date:  2012-01-31       Impact factor: 4.354

8.  'Click cyclic ADP-ribose': a neutral second messenger mimic.

Authors:  Joanna M Swarbrick; Richard Graeff; Clive Garnham; Mark P Thomas; Antony Galione; Barry V L Potter
Journal:  Chem Commun (Camb)       Date:  2014-01-23       Impact factor: 6.222

9.  CD38 Structure-Based Inhibitor Design Using the N1-Cyclic Inosine 5'-Diphosphate Ribose Template.

Authors:  Christelle Moreau; Qun Liu; Richard Graeff; Gerd K Wagner; Mark P Thomas; Joanna M Swarbrick; Satoshi Shuto; Hon Cheung Lee; Quan Hao; Barry V L Potter
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

10.  Cyclic adenosine 5'-diphosphate ribose analogs without a "southern" ribose inhibit ADP-ribosyl cyclase-hydrolase CD38.

Authors:  Joanna M Swarbrick; Richard Graeff; Hongmin Zhang; Mark P Thomas; Quan Hao; Barry V L Potter
Journal:  J Med Chem       Date:  2014-10-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.